Previous 10 | Next 10 |
Equillium (NASDAQ:EQ) began a phase 3 trial of its drug itolizumab in patients with acute graft-versus-host disease (aGVHD). GVHD is an inflammatory response by the immune system after a bone marrow transplant. The disease can be caused after the immune cells of the donor attack the recipient...
Pivotal study to enroll up to 200 patients Global study with sites expected in North America, Europe, Asia and Australia Primary endpoint assessment of Complete Response at Day 29 Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced the appointment of Barbara Troupin, M.D., to the Equillium Board of Directors...
Gainers: Creative Medical Technology (NASDAQ:CELZ) +33%. HOOKIPA Pharma (NASDAQ:HOOK) +18%. Zynex ZYXI +17%. AMN Healthcare Services (NYSE:AMN) +15%. ShockWave Medical (NASDAQ:SWAV) +10%. Losers: Baudax Bio (NASDAQ:BXRX) -11%. Nuvectis Pharma (NASDAQ:NVCT)...
Equillium (NASDAQ:EQ) acquired Bioniz Therapeutics, granting EQ exclusive worldwide rights to all current and future Bioniz products. The consideration is comprised of an all-stock upfront payment of ~5.7M unregistered EQ shares issuable to Bioniz stockholders, which represents ~19.3% of Equi...
Acquisition includes two first-in-class clinical-stage assets and proprietary product discovery platform Creates a robust immunology pipeline with significant value-creating milestones, and provides a strong clinical and research team with complementary expertise in immuno...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced timing updates for two separate conference presentations. Equillium will now participate in ...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will participate in a fireside chat presentation at the SVB Leerink Virtual Global Healt...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that three abstracts were accepted for presentation at the Transplantation & Cellular Me...
First data to demonstrate the contribution of CD6-ALCAM and T-cells to the pathogenesis of lupus nephritis Largest, most comprehensive cohort of lupus nephritis patients analy z ed to date supports soluble ALCAM as a biomarker for disease activity Equillium, Inc....
News, Short Squeeze, Breakout and More Instantly...
Q2 ending cash, cash equivalents and short-term investments totaled approximately $33.3 million, an increase of approximately $1.0 million compared to the amount at the end of Q1 Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutic...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will be participating in the Leerink Partners Therapeutic Forum: I&I and Metabolism, as well as the Jone...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it expects to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effe...